Clinical Trials Browser

Thyroid Cancer, Papillary × 30 days × Clear all

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2 Active not recruiting

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT07584447 2026-06-01

Clinical Utility of Preoperative Thyroid GuidePx® Testing

Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

NCT02568267 2026-05-27

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT06959641 2026-05-22

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT07376837 2026-05-19

PTC-RFA

Phase NA Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary